Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Net Cash Flow: 2011-2025

Historic Net Cash Flow for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to $3.2 million.

  • Fennec Pharmaceuticals' Net Cash Flow rose 218.58% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.4 million, marking a year-over-year decrease of 165.80%. This contributed to the annual value of $13.4 million for FY2024, which is 227.23% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Net Cash Flow is $3.2 million, which was up 181.66% from -$4.0 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Net Cash Flow's 5-year high stood at $37.9 million during Q1 2024, with a 5-year trough of -$13.7 million in Q4 2024.
  • Moreover, its 3-year median value for Net Cash Flow was -$3.4 million (2023), whereas its average is -$166,091.
  • Examining YoY changes over the last 5 years, Fennec Pharmaceuticals' Net Cash Flow showed a top increase of 804.22% in 2024 and a maximum decrease of 1,673.10% in 2024.
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' Net Cash Flow stood at -$3.0 million in 2021, then skyrocketed by 770.96% to -$6.0 million in 2022, then skyrocketed by 114.55% to $870,000 in 2023, then plummeted by 1,673.10% to -$13.7 million in 2024, then spiked by 218.58% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, -$4.0 million for Q2 2025, and -$4.0 million during Q1 2025.